Article
Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.
Pharmaceutical research - 16 Jul 2020
Moeung Sotheara, Chevreau Christine, Marsili Sabrina, Massart Christophe, Fléchon Aude, Delva Rémy, Gravis Gwenaëlle, Lotz Jean-Pierre, Bay Jacques-Olivier, Gross-Goupil Marine, Filleron Thomas, Delmas Caroline, Lafont Thierry, Chatelut Etienne, Thomas Fabienne
Abstract excerpt
BACKGROUND: Etoposide dosing is based on body surface area. We evaluated if further dose individualization would be required for high dose (HD) etoposide within the TI-CE (taxol, ifosfamide, carboplatin, and etoposide) protocol. METHODS: Eighty-eight patients received 400 mg/m2/day of etoposide as a 1-hour IV infusion on 3 consecutive days over 3 cycles as part of a phase II trial evaluating efficacy of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.